Short answer
Tyra Biosciences, Inc. (TYRA) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Tyra Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the substantive financial details
- Disclosure furnished under Regulation FD and generally not subject to Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- September 2026 SURF302 readout: safety data from 40+ patients and efficacy data from 20+ patients across 50 mg and 60 mg cohorts
- BEACH301 fifth dose level adds 0.625 mg/kg; approximately 25-child safety-sentinel data expected end-Q1 2027
- Cash, equivalents and marketable securities $353.9M, supporting operations into 2H 2028
- Additional $250.0M ATM capacity increases funding flexibility but creates potential shareholder dilution
- Q2 net loss $45.6M versus $28.1M; R&D rose to $39.2M from $24.3M as pivotal-intent programs advanced
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tyra Biosciences, Inc. 8-K filings
Get the next TYRA 8-K as it lands
Follow TYRA for push alerts, or ask the research agent what this filing means.